Explore

AP News AP News
OxyContin maker Purdue Pharma's settlement, by the numbers

OxyContin maker Purdue Pharma's settlement, by the numbers

OxyContin maker Purdue Pharma's deal to resolve thousands of lawsuits over the toll of opioids is taking effect Friday and the company is being replaced by a new entity
Rapid Read Rapid Read
Purdue Pharma to Dissolve Following Judge's Approval of Criminal Sentence

Purdue Pharma to Dissolve Following Judge's Approval of Criminal Sentence

Purdue Pharma, the maker of OxyContin, is set to dissolve following a federal judge's approval of its criminal sentence. This decision is part of a massive legal settlement resolving thousands of lawsuits related to the opioid crisis. U.S. District Judge Madeline Cox Arleo delivered the sentence after hearing impact statements from individuals affected by the epidemic, which has been linked to over 900,000 deaths in the U.S. since 1999. The company will be replaced by an entity focused on public good, marking a significant step in addressing the opioid crisis.
Reuters Reuters
US consumer finance watchdog narrows Biden-era anti-discrimination rule on small business lending

US consumer finance watchdog narrows Biden-era anti-discrimination rule on small business lending

By Douglas Gillison NEW YORK, April 30 (Reuters) - The U.S.
Reuters Reuters
Saks Global sends its bankruptcy plan to a creditor vote

Saks Global sends its bankruptcy plan to a creditor vote

By Dietrich Knauth NEW YORK, May 1 (Reuters) - Saks Global received court approval on Friday to send its bankruptcy plan to creditors for a vote, asking them to approve a restructuring that would wipe out the company's equity and hand control over to its senior lenders. U.S.
AP News AP News
OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

OxyContin maker Purdue Pharma has been ordered to pay $225 million in a criminal case related to how it sold its blockbuster opioid painkiller
AP News AP News
Judge approves OxyContin maker Purdue Pharma's criminal sentence, a last step before it dissolves

Judge approves OxyContin maker Purdue Pharma's criminal sentence, a last step before it dissolves

OxyContin maker Purdue Pharma has been ordered to pay $225 million in a criminal case related to how it sold its blockbuster opioid painkiller
Rapid Read Rapid Read
Purdue Pharma Sentenced in Opioid Case, Sackler Family Avoids Charges

Purdue Pharma Sentenced in Opioid Case, Sackler Family Avoids Charges

Purdue Pharma has been sentenced to pay $225 million in fines to the U.S. Justice Department as part of a criminal settlement related to its role in the opioid crisis. The company admitted to misleading the public about the safety of OxyContin and engaging in illegal marketing practices. Despite the settlement, members of the Sackler family, who own Purdue Pharma, will not face criminal charges. The settlement follows years of legal battles over the company's bankruptcy and its role in the opioid epidemic, which has claimed hundreds of thousands of lives in the U.S.
Rapid Read Rapid Read
Federal Judge to Order Purdue Pharma to Forfeit $225 Million in Justice Department Case

Federal Judge to Order Purdue Pharma to Forfeit $225 Million in Justice Department Case

A federal judge is set to conduct a sentencing hearing for Purdue Pharma, where the company is expected to be ordered to forfeit $225 million to the Justice Department. This development is part of a broader legal case involving Purdue Pharma, which has been under scrutiny for its role in the opioid crisis. The company has faced numerous lawsuits and legal challenges over the years, primarily due to its marketing practices related to OxyContin, a powerful opioid painkiller. The forfeiture is part of a settlement agreement aimed at addressing the company's alleged misconduct and its impact on public health.
Rapid Read Rapid Read
Judge Approves Sentence for Purdue Pharma in OxyContin Case

Judge Approves Sentence for Purdue Pharma in OxyContin Case

A judge in Newark has approved a criminal sentence for Purdue Pharma, the manufacturer of OxyContin. This decision marks a significant development in the legal proceedings against the company, which has been at the center of the opioid crisis in the United States. Purdue Pharma has faced numerous lawsuits and legal challenges over its role in the widespread addiction and overdose deaths linked to its painkiller, OxyContin. The sentencing is part of a broader effort to hold pharmaceutical companies accountable for their contributions to the opioid epidemic, which has claimed hundreds of thousands of lives across the country.
Rapid Read Rapid Read
Judge Approves Sentence for OxyContin Maker Purdue Pharma in Newark

Judge Approves Sentence for OxyContin Maker Purdue Pharma in Newark

A judge in Newark has approved a criminal sentence for Purdue Pharma, the maker of OxyContin. This decision is part of ongoing legal proceedings against the company, which has faced significant scrutiny and legal challenges due to its role in the opioid crisis. Purdue Pharma has been accused of contributing to widespread addiction and overdose deaths through its aggressive marketing of OxyContin. The sentencing marks a significant development in the legal battles surrounding the company, which has been under intense public and legal pressure to account for its actions.
Reuters Reuters
Trump administration appeals judge's order upending Kennedy's vaccine policies

Trump administration appeals judge's order upending Kennedy's vaccine policies

By Nate Raymond BOSTON, April 29 (Reuters) - The Trump administration on Wednesday appealed a federal judge's ruling blocking key elements of Health Secretary Robert F. Kennedy Jr.'s push to reshape U.S. vaccine policy, including reducing the number of routinely recommended childhood vaccinations.
Reuters Reuters
Wall Street ends mixed after Fed decision, big tech earnings on tap

Wall Street ends mixed after Fed decision, big tech earnings on tap

By Stephen Culp and Niket Nishant NEW YORK, April 29 (Reuters) - Wall Street oscillated on Wednesday, as investors juggled spiking crude prices, the U.S. Federal Reserve's interest rate decision, and a quartet of high-profile earnings to be released after the closing bell.